StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Tarsus Pharmaceuticals's total assets was $611.14M at Jun 30, 2026. For fiscal 2025 it was $562.16M, up 49.1% from the year before. The highest annual figure on record is $562.16M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$562.16M+49.1%
FY2024Dec 31, 2024$376.99M+42.0%
FY2023Dec 31, 2023$265.49M+16.5%
FY2022Dec 31, 2022$227.86M+27.4%
FY2021Dec 31, 2021$178.91M+4.0%
FY2020Dec 31, 2020$171.97M+194.9%
FY2019Dec 31, 2019$58.32M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$611.14M+23.5%
Q1 FY2026Mar 31, 2026$581.14M+16.1%
Q4 FY2025Dec 31, 2025$562.16M+49.1%
Q3 FY2025Sep 30, 2025$534.56M+42.1%
Q2 FY2025Jun 30, 2025$494.99M+31.4%
Q1 FY2025Mar 31, 2025$500.75M+43.4%
Q4 FY2024Dec 31, 2024$376.99M+42.0%
Q3 FY2024Sep 30, 2024$376.30M+40.2%
Q2 FY2024Jun 30, 2024$376.84M+99.5%
Q1 FY2024Mar 31, 2024$349.28M+65.4%
Q4 FY2023Dec 31, 2023$265.49M+16.5%
Q3 FY2023Sep 30, 2023$268.33M+13.5%
Q2 FY2023Jun 30, 2023$188.93M-25.3%
Q1 FY2023Mar 31, 2023$211.21M+16.4%
Q4 FY2022Dec 31, 2022$227.86M+27.4%
Q3 FY2022Sep 30, 2022$236.47M+24.2%
Q2 FY2022Jun 30, 2022$252.83M+24.3%
Q1 FY2022Mar 31, 2022$181.48M-6.4%
Q4 FY2021Dec 31, 2021$178.91M+4.0%
Q3 FY2021Sep 30, 2021$190.41M+106.6%
Q2 FY2021Jun 30, 2021$203.45M+248.9%
Q1 FY2021Mar 31, 2021$193.95M–
Q4 FY2020Dec 31, 2020$171.97M–
Q3 FY2020Sep 30, 2020$92.19M–
Q4 FY2019Dec 31, 2019$58.32M–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?